Janux Therapeutics vs Nanobiotix
JANX and NBTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JANX and NBTX compare
Nanobiotix keeps more of each dollar of sales as profit, with a net margin of −73.5% compared with −429% at Janux Therapeutics.
Janux Therapeutics scores higher on the StockData Score (12 against 3 for Nanobiotix), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JANX | NBTX |
|---|---|---|
| Size and price | ||
| Market cap | $695M | – |
| Share price | $11.37 | $30.66 |
| Change, 1 year | −60.1% | 42.1% |
| Change, 5 years | −36.4% | 231% |
| Beta (5Y) | 1.60 | 0.47 |
| Employees | 109 | 97 |
| StockData Score | ||
| Total score | 12 (better) | 3 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 29.8× | – |
| P/B | 0.8× | – |
| FCF yield | −7.8% | – |
| Fair value | $16.54 | – |
| Margin of safety | 31.3% | – |
| Growth | ||
| Revenue growth (TTM) | 133% | – |
| Revenue growth, 5Y average | – | 67.0% |
| Profitability | ||
| Operating margin | −599% | −33.2% (better) |
| Net margin | −429% | −73.5% (better) |
| FCF margin | −233% | −104% (better) |
| Return on equity | −10.6% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −0.7× |
| Current ratio | 17.69 (better) | 1.44 |
| Altman Z-score | 5.85 | – |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 101% | 12.0% |
| Held by insiders | 21.3% | 0.00% |
| Insider net buying, 12 months | −$457K | – |
| Short interest, % of float | 11.1% | – |
Go deeper
- JANX stock overview
- JANX income statement
- JANX valuation and score
- NBTX stock overview
- NBTX income statement
- NBTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.